Two new dermal fillers received FDA approval for cheek and lip indications, adding to an already crowded filler market dominated by Allergan Aesthetics, Galderma, and Merz. The new entrants will compete on rheology, longevity claims, and pricing.
Injectables
Two New Fillers Receive FDA Approval for Cheeks and Lips
Two new dermal fillers cleared FDA for cheek and lip indications, expanding the competitive filler landscape.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Two new fillers cleared FDA for cheeks and lips, intensifying competition in mature market.
For practices, new filler approvals mean more vendor options but also margin pressure. The market is mature enough that new launches must justify switching costs—either through superior clinical data, better economics, or both. Practices should evaluate these new fillers against existing Restylane, Juvéderm, and Belotero portfolios on cost-per-unit, patient satisfaction, and rebate programs before committing to inventory.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.